Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Up 69.2% in July

Key Points

• Genenta Science S.p.A. experienced a significant increase in short interest, rising by 69.2% to 6,600 shares as of July 15th.
• Institutional investors hold 15.13% of Genenta Science's stock, with notable increases in holdings from Citadel Advisors and Allianz SE.
• Shares of Genenta Science traded up 2.2% recently, with a current price of $3.78 and a 52-week range between $2.74 and $7.28.

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - Get Free Report) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 6,600 shares, agrowthof69.2% from the June 30th total of 3,900 shares. Based on an average daily trading volume, of 12,300 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily trading volume, of 12,300 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Investors Weigh In On Genenta Science

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in shares of Genenta Science during the 4th quarter valued at $46,000. Algebris UK Ltd boosted its holdings in shares of Genenta Science by 122.2% during the 1st quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock worth $368,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Allianz SE raised its position in shares of Genenta Science by 126.2% during the 1st quarter. Allianz SE now owns 233,550 shares of the company's stock valued at $927,000 after buying an additional 130,300 shares during the period. 15.13% of the stock is owned by institutional investors.

Genenta Science Stock Performance

Shares of GNTA stock traded down $0.06 on Friday, reaching $3.75. The stock had a trading volume of 738 shares, compared to its average volume of 4,516. The company has a 50 day simple moving average of $3.77 and a 200 day simple moving average of $3.91. Genenta Science has a 1 year low of $2.74 and a 1 year high of $7.28.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.